Compare LBRDK & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDK | DNTH |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | N/A | 2018 |
| Metric | LBRDK | DNTH |
|---|---|---|
| Price | $30.78 | $99.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $109.28 | $29.48 |
| P/E Ratio | $10.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.08 | $18.08 |
| 52 Week High | $91.79 | $102.37 |
| Indicator | LBRDK | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 61.44 |
| Support Level | $29.37 | $79.27 |
| Resistance Level | $34.95 | N/A |
| Average True Range (ATR) | 1.76 | 5.39 |
| MACD | 0.04 | 0.67 |
| Stochastic Oscillator | 7.81 | 82.57 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.